LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 108 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,935,485 | $40,874,517 | 3.42% |
| Defender Capital, LLC. | 5,093,535 | $5,959,436 | 2.41% |
| Raffles Associates | 1,536,946 | $1,798,230 | 2.10% |
| Prescott General Partners LLC | 1,851,851 | $2,166,666 | 0.18% |
| DAFNA Capital Management LLC | 140,000 | $163,800 | 0.05% |
| Fort Sheridan Advisors LLC | 83,931 | $98,199 | 0.03% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $52,650 | 0.03% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 781,766 | $914,666 | 0.02% |
| ETF MANAGERS GROUP, LLC | 353,991 | $414,169 | 0.02% |
| Straight Path Wealth Management | 16,200 | $18,954 | 0.02% |